摘要
目的：探讨替吉奥胶囊联合奥沙利铂化疗对进展期胃癌根治术患者的影响。方法选择2011年1月～2013年8月湖州市中医院收治的86例进展期胃癌患者为研究对象，将其随机分为对照组和观察组，各43例。对照组先给予奥沙利铂化疗，再行腹腔镜胃癌根治术。观察组先给予替吉奥联合奥沙利铂化疗，再行腹腔镜胃癌根治术。观察比较两组患者的临床疗效、不良反应及CD3＋T细胞、CD4＋T细胞、CD8＋T细胞水平。结果观察组总有效率为65.12%，显著高于对照组（41.86%），差异有统计学意义（P〈0.05）。观察组患者白细胞下降发生率（11.63%）、血小板下降发生率（11.63%）、胃肠道反应发生率（16.28%）均显著少于对照组（30.23%、25.58%、34.88%），差异均有统计学意义（P〈0.05）。观察组R0切除率（65.12%）高于对照组（37.21%），差异有高度统计学意义（P〈0.01）。观察组术后复发率（9.30%）低于对照组（41.86%），病死率（4.65%）低于对照组（23.26%），差异有统计学意义（P〈0.01、P〈0.05）。观察组治疗后CD4＋T细胞、CD8＋T细胞、CD4＋/CD8＋水平均高于对照组，差异均有统计学意义（P〈0.01或P〈0.05）。结论术前接受替吉奥胶囊联合奥沙利铂化疗能有效提高进展期胃癌根治术患者的疗效，降低术后复发率、病死率，与正常人比较患者免疫功能明显下降，但化疗后可以提高机体CD4＋T细胞、CD4＋/CD8＋的表达水平。
Objective To investigate the effect of Tegafur Gimeracil Oteracil Potassium Capsule combined with Oxali-platin chemotherapy for patients with radical gastrectomy for advanced gastric cancer. Methods 86 cases of patients with advanced gastric cancer admitted to Huzhou Hospital of Traditional Chinese Medicine from January 2011 to Au-gust 2013 were chosen as research objects, and they were randomly divided into control group and observation group, with 43 cases in each group. The control group was given Oxaliplatin chemotherapy first, then they were taken laparo-scopic radical gastrectomy; the observation group was given Tegafur Gimeracil Oteracil Potassium Capsule combined with Oxaliplatin chemotherapy first, then they were taken laparoscopic radical gastrectomy. The clinical effect, adverse reactions and levels of CD3＋T cell, CD4＋T cell, CD8＋T cell of the two groups were observed and compared. Results The total efficiency of the observation group was 65.12%, which was higher than that of the control group （41.86%）, the dif-ference was statistically significant （P 〈 0.05）. The incidence of leukocyte decrease （11.63%）, platelet descend （11.63%）, gastrointestinal reactions （16.28%） of the observation group were all less than those of control group （30.23%, 25.58%, 34.88%）, the differences were all statistically significant （P〈0.05）. The R0 resection rate of observation group （65.12%） was higher than that of control group （37.21%）, with a highly significant difference （P〈0.01）. The recurrence rate after operation of observation group （9.30%） was lower than that of control group （41.86%）, fatality rate （4.65%） was lower than that of contro group （23.26%）, with highly significant differences （P〈 0.01, P〈 0.05）. After treatment, the CD4＋T cell, CD8＋T cell, CD4＋/CD8＋of observation group were all higher than those of control group, there were sta-tistically significant differences （P〈 0.01 or P〈 0.05）. Conclusion Tegafur Gimeracil O
出处
《中国医药导报》
CAS
2015年第17期109-112,共4页
China Medical Herald
基金
浙江省卫生厅中药医院制剂研究计划项目(2009YB033)
关键词
胃癌
替吉奥胶囊
奥沙利铂
腹腔镜胃癌根治术
Gastric cancer
Tegafur Gimeracil Oteracil Potassium Capsule
Oxaliplatin
Laparoscopic radical gastrectomy
